longevitywatch

Can GLP-1 agonists reduce cravings for alcohol and nicotine?

Preliminary evidence

There are serious indications that GLP-1 agonists such as semaglutide can curb cravings for alcohol and nicotine, but clinical evidence from trials in humans is still too limited to establish this with certainty. Do not use them outside their official indication for this purpose for the time being.

Animal research shows that GLP-1 agonists such as exenatide and liraglutide substantially reduce alcohol consumption. In mice, rats and monkeys, the motivation to drink alcohol, self-administration and relapse all decreased. The mechanism most likely runs through the brain's reward system, in particular via the signalling molecule dopamine. Stress regulation and cognitive processes may also play a role, although the precise mechanism has not yet been fully elucidated.

In humans the picture is less clear-cut, but there are genuine indications. Research based on Swedish patient data (more than 227,000 people with an alcohol use disorder) showed that semaglutide was associated with a hazard ratio of 0.64 for hospital admission due to alcohol-related problems, and liraglutide with a hazard ratio of 0.72, compared with periods of non-use in the same individuals. That is a stronger association than has been found for officially approved medications for alcohol addiction. However, this is not a randomised experiment, so cause and effect cannot be established.

For nicotine, a large analysis of electronic health records in the US, involving more than 222,000 people with diabetes, points to a clear difference: semaglutide users had significantly fewer healthcare contacts for tobacco addiction than people using other diabetes medications, including other GLP-1 agonists. Notably, that reduction occurred within 30 days of starting treatment. Here too, this represents an association in patient data, not proof that semaglutide itself is responsible.

Clinical evidence from actual trials is still scarce. Of the 5 trials in humans that met the selection criteria, 3 showed a positive effect on alcohol or nicotine addiction; 2 found no effect. Both reviews examining this conclude that it is too early to prescribe GLP-1 agonists outside their official indication for addiction. Genetic research also provides context: people with certain variants in the GLP-1 receptor gene have a higher risk of alcohol addiction and drink more on average when given intravenous access to alcohol. This suggests that the GLP-1 system is biologically relevant to addictive behaviour, but it does not prove a causal relationship.

The evidence
8 studies · 1 systematic review · ≈ 450,000 participants

This answer draws on animal research (mice, rats, monkeys), large analyses of patient data (a Swedish cohort of more than 227,000 people, a US records analysis of more than 222,000 people), and a handful of clinical trials in humans. The animal research is consistent and robust; the human evidence is based on associations in patient data and is therefore vulnerable to confounding factors. The researchers behind the clinical reviews emphasise that only 5 usable trials were available and that the results are mixed. The evidence for a causal effect in humans is therefore not yet conclusive.

Last checked: November 2026 · how this was judged
Related answers

Do GLP-1 medications cause suicidal thoughts?

The available research gives no indication that GLP-1 medications cause suicidal thoughts; several large studies actually point to a lower risk. If you have doubts or concerns, discuss them with your doctor.

No · Moderate evidence

Do you lose muscle mass when losing weight with a GLP-1 medication?

With GLP-1 medications you do indeed lose muscle mass alongside fat, but you can largely limit this by combining resistance training with adequate protein intake. If you are older or already frail, discuss this risk explicitly with your doctor before starting.

Moderate evidence

Do GLP-1 medications (such as Ozempic) help you age more healthily?

For people with cardiovascular disease, kidney disease, or fatty liver disease, GLP-1 medications offer proven benefits that are also relevant at older ages. As an anti-ageing intervention in healthy people, their use is not yet supported by evidence.

Moderate evidence

Does eating less help your cells clean themselves more effectively?

Intermittent fasting shows preliminary signals that it modestly supports cellular self-cleaning. Simply eating less or reducing protein intake does not demonstrably do the same.

Preliminary evidence

Can GLP-1 agonists improve heart function?

Semaglutide and tirzepatide demonstrably reduce the chance of heart failure worsening in people with a specific form of heart failure. If you have this condition or type 2 diabetes, discuss with your cardiologist whether these medicines are appropriate for you.

Yes · Strong evidence

Does GLP-1 help you feel less hungry?

GLP-1 demonstrably reduces hunger, both as a hormone the body makes naturally and through medicines such as semaglutide. When using those medicines, people lose on average nearly 11% of their body weight.

Yes · Moderate evidence
Related research
18 Nov
Vasodilation and vibration improve brain fluid drainage in people
16 Nov
Brain map of basal ganglia aids Parkinson’s therapy in mice
15 Nov
Diet and prescription drugs appear to slow biological aging; supplements do not
Don't see your question?
Ask it and we'll look it up for you.
Ask a question →
Newsletter

Stay in the loop

Every Thursday, the most important longevity research in your inbox, focused on what you follow.